Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Int J Biol Macromol ; 260(Pt 1): 129397, 2024 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-38219933

RESUMEN

Biotechnological advancements require the physicochemical alteration of molecules to enhance their biological efficacy for the effective treatment of gastric ulcers. The study aimed to produce a polyelectrolytic compound from red angico gum (AG) by carboxymethylation, evaluate its physicochemical characteristics and investigate gastric protection against ethanol-induced ulcers. AG and carboxymethylated angico gum (CAG) were characterized by Fourier transform infrared spectroscopy, determination of the degree of substitution and gel permeation chromatography (GPC) and 13C NMR techniques. The results demonstrated that the modification of the polymer was satisfactory, presenting conformational changes e improving the interaction with the gastric mucosa. AG and CAG reduced macroscopic and microscopic damage such as edema, hemorrhage and cell loss caused by exposure of the mucosa to alcohol. Both demonstrated antioxidant activity in vitro, and in vivo, pretreatment with gums led to the restoration of superoxide dismutase and glutathione levels compared to the injured group. Concurrently, the levels of malondialdehyde and nitrite decreased. Atomic force microscopy showed that CAG presented better conformational properties of affinity and protection with the gastric mucosa compared to AG in the acidic pH. Based on our findings, it is suggested that this compound holds promise as a prospective product for future biotechnological applications.


Asunto(s)
Colubrina , Fabaceae , Úlcera Gástrica , Estudios Prospectivos , Estómago , Antioxidantes/efectos adversos , Mucosa Gástrica , Úlcera Gástrica/inducido químicamente , Úlcera Gástrica/tratamiento farmacológico , Extractos Vegetales/química
2.
Eur J Pharmacol ; 902: 174113, 2021 Jul 05.
Artículo en Inglés | MEDLINE | ID: mdl-33901460

RESUMEN

The transient receptor potential vanilloid channel 4 (TRPV4) is associated with the development of several pathologies, particularly gastric disorders. However, there are no studies associating this receptor with the pathophysiology of gastric erosions. The aim of this study was to investigate the role of TRPV4 in the development of ethanol-induced gastric damage in vivo. Gastric lesions were induced by ethanol in Swiss mice pretreated with TRPV4 antagonists, GSK2193874 (0.1; 0.3 and 0.9 mg/kg) or Ruthenium red (0.03; 0.1 or 0.3 mg/kg) or its agonist, GSK1016790A (0.9 mg/kg). Gastric mucosal samples were taken for histopathology, immunohistochemistry, atomic force microscopy and evaluation of antioxidant parameters. The gastric mucus content and TRPV4 mRNA expression were analyzed. Ethanol exposure induced upregulation of gastric mRNA and protein expression of TRPV4. TRPV4 blockade promoted gastroprotection against ethanol-induced injury on macro- and microscopic levels, leading to reduced hemorrhage, cell loss and edema and enhanced gastric mucosal integrity. Moreover, an increase in superoxide dismutase (SOD) and glutathione (GSH) activity was observed, followed by a decrease in malondialdehyde (MDA) levels. TRPV4 blockade during alcohol challenge reestablished gastric mucus content. The combination of TRPV4 agonist and ethanol revealed macroscopic exacerbation of gastric damage area. Our results confirmed the association of TRPV4 with the development of gastric injury, showing the importance of this receptor for further investigations in the field of gastrointestinal pathophysiology and pharmacology.


Asunto(s)
Úlcera Gástrica/metabolismo , Úlcera Gástrica/fisiopatología , Canales Catiónicos TRPV/agonistas , Canales Catiónicos TRPV/metabolismo , Animales , Edema/inducido químicamente , Edema/metabolismo , Etanol/toxicidad , Mucosa Gástrica/efectos de los fármacos , Mucosa Gástrica/lesiones , Mucosa Gástrica/metabolismo , Glutatión/metabolismo , Leucina/análogos & derivados , Leucina/farmacología , Leucina/uso terapéutico , Masculino , Malondialdehído/metabolismo , Ratones , Estrés Oxidativo/efectos de los fármacos , Piperidinas/farmacología , Piperidinas/uso terapéutico , Quinolinas/farmacología , Quinolinas/uso terapéutico , Rojo de Rutenio/farmacología , Rojo de Rutenio/uso terapéutico , Úlcera Gástrica/inducido químicamente , Úlcera Gástrica/patología , Sulfonamidas/farmacología , Sulfonamidas/uso terapéutico , Superóxido Dismutasa/metabolismo , Canales Catiónicos TRPV/antagonistas & inhibidores , Canales Catiónicos TRPV/genética , Regulación hacia Arriba/efectos de los fármacos
3.
J Pharm Pharmacol ; 72(12): 1715-1731, 2020 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-32737883

RESUMEN

OBJECTIVES: The oral rehydration solution is the most efficient method to treat cholera; however, it does not interfere in the action mechanism of the main virulence factor produced by Vibrio cholerae, the cholera toxin (CT), and this disease still stands out as a problem for human health worldwide. This review aimed to describe therapeutic alternatives available in the literature, especially those related to the search for molecules acting upon the physiopathology of cholera. KEY FINDINGS: New molecules have offered a protection effect against diarrhoea induced by CT or even by infection from V. cholerae. The receptor regulator cystic fibrosis channel transmembrane (CFTR), monosialoganglioside (GM1), enkephalinase, AMP-activated protein kinase (AMPK), inhibitors of expression of virulence factors and activators of ADP-ribosylarginine hydrolase are the main therapeutic targets studied. Many of these molecules or extracts still present unclear action mechanisms. CONCLUSIONS: Knowing therapeutic alternatives and their molecular mechanisms for the treatment of cholera could guide us to develop a new drug that could be used in combination with the rehydration solution.


Asunto(s)
Antibacterianos/uso terapéutico , Cólera/tratamiento farmacológico , Vibrio cholerae/efectos de los fármacos , Animales , Antibacterianos/efectos adversos , Cólera/diagnóstico , Cólera/microbiología , Toxina del Cólera/metabolismo , Terapia Combinada , Fluidoterapia , Interacciones Huésped-Patógeno , Humanos , Terapia Molecular Dirigida , Soluciones para Rehidratación/uso terapéutico , Resultado del Tratamiento , Vibrio cholerae/metabolismo , Vibrio cholerae/patogenicidad , Factores de Virulencia/metabolismo
5.
Eur J Pharmacol ; 856: 172410, 2019 Aug 05.
Artículo en Inglés | MEDLINE | ID: mdl-31132357

RESUMEN

Alendronate is a bisphosphonate widely used for the treatment of osteoporosis; however, one of its main adverse reactions is gastric ulcer. Metformin is an oral antihyperglycemic agent that has several beneficial effects, including healing, gastroprotective and anti-tumoral action. This study aimed to evaluate the gastroprotective activity of metformin in alendronate-induced gastric damage in normoglycemic and hyperglycemic rats. The treatment with 100 mg/kg of metformin showed a significant gastroprotective effect in damage induced by alendronate (50 mg/kg) in macroscopic analysis and the analysis of light microscopy and atomic force microscopy. The results suggested metformin decreased the inflammatory response by reducing the expression of proinflammatory cytokines (TNF-α, IL-1ß and IL-6), myeloperoxidase activity, and malondialdehyde levels. Also, the results suggested that metformin induces the maintenance of basal levels of collagen and increase the production of mucus. Interestingly, with the presence of the AMPK inhibitor (Compound C), metformin presented impairment of its gastroprotective action. The gastroprotective effect of metformin might be related to the activation of the AMPK pathway. These findings revealed that metformin has a gastroprotective action and may be considered a therapeutic potential for the prevention and treatment of gastric lesions induced by alendronate.


Asunto(s)
Alendronato/efectos adversos , Glucemia/metabolismo , Citoprotección/efectos de los fármacos , Hiperglucemia/patología , Metformina/farmacología , Estómago/efectos de los fármacos , Estómago/patología , Alendronato/antagonistas & inhibidores , Animales , Colágeno/metabolismo , Citocinas/metabolismo , Mucosa Gástrica/efectos de los fármacos , Mucosa Gástrica/metabolismo , Malondialdehído/metabolismo , Peroxidasa/metabolismo , Ratas , Ratas Wistar
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...